CIP
KYNB

Convergence Investment Partners’s Kyntra Bio KYNB Stock Holding History

Convergence Investment Partners’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-148
Closed -$137K – 257
2019
Q3 		$137K Buy
+148
New +$163K 0.04% 266

Other funds holding KYNB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Convergence Investment Partners's KYNB Position: Q4 2019 in Review

Convergence Investment Partners sold out of Kyntra Bio (KYNB) in Q4 2019, closing a stake of 148 shares — an estimated $137K sold.

Convergence Investment Partners first reported a position in KYNB in Q3 2019 and held it in 1 quarter. The position peaked at $137K in Q3 2019. 213 funds tracked by Wall St. Rank hold KYNB as of Q4 2019.

  • Convergence Investment Partners reported no remaining Kyntra Bio position as of Q4 2019 after selling out during the quarter.
  • Convergence Investment Partners sold 148 Kyntra Bio shares in Q4 2019, an estimated $137K.
  • Convergence Investment Partners first reported a position in Kyntra Bio in Q3 2019 and held it in 1 quarter.
  • Convergence Investment Partners's Kyntra Bio position peaked at $137K in Q3 2019.
  • 213 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2019.

Based on Convergence Investment Partners's 13F filing for Q4 2019, filed 22 Jan 2020.